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Background: Findings from observational studies suggest that sex hormone-binding globulin (SHBG) and
endogenous sex hormones may be mediators of the putative relation between coffee consumption and lower risk
of type 2 diabetes. The objective of this study was to evaluate the effects of caffeinated and decaffeinated coffee
on SHBG and sex hormone levels.
Findings: After a two-week run-in phase with caffeine abstention, we conducted an 8-week parallel-arm
randomized controlled trial. Healthy adults (n = 42) were recruited from the Boston community who were regular
coffee consumers, nonsmokers, and overweight. Participants were randomized to five 6-ounce cups of caffeinated
or decaffeinated instant coffee or water (control group) per day consumed with each meal, mid-morning, and mid-
afternoon. The main outcome measures were SHBG and sex hormones [i.e., testosterone, estradiol,
dehydroepiandrosterone sulfate].
No significant differences were found between treatment groups for any of the studied outcomes at week 8. At
4 weeks, decaffeinated coffee was associated with a borderline significant increase in SHBG in women, but not in
men. At week 4, we also observed several differences in hormone concentrations between the treatment groups.
Among men, consumption of caffeinated coffee increased total testosterone and decreased total and free estradiol.
Among women, decaffeinated coffee decreased total and free testosterone and caffeinated coffee decreased total
testosterone.
Conclusions: Our data do not indicate a consistent effect of caffeinated coffee consumption on SHBG in men or
women, however results should be interpreted with caution given the small sample size. This is the first
randomized trial investigating the effects of caffeinated and decaffeinated coffee on SHBG and sex hormones and
our findings necessitate further examination in a larger intervention trial.
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Coffee consumption has been consistently associated
with a lower risk of type 2 diabetes (T2DM), but the
underlying mechanisms remain unclear. Data from ob-
servational studies suggest that sex hormone-binding
globulin (SHBG) and endogenous sex hormones may
modulate glycemia and risk of T2DM in men and
women [1-5]. Caffeinated coffee consumption has been
found to be associated with higher SHBG levels in data
from cross-sectional studies in women [2,6-8]. It has
been hypothesized that SHBG may be an intermediate
pathway to explain the putative effect of coffee on lower-
ing the risk of T2DM [3].
We conducted an 8-week parallel-arm randomized
trial to determine the effects of caffeinated and decaffei-
nated coffee on risk factors for T2DM. To our know-
ledge, there have been no randomized trials to
investigate this research question.
Participants and methods
The details of this study have been previously described
[9]. Briefly, eligible participants were overweight (body
mass index 25–35 kg/m2), nonsmoking men and women
aged 18 years or older who habitually consumed coffee
(at least two cups per day). Exclusion criteria included
the presence of diabetes, heart disease, stroke, hyperten-
sion, alcoholism or substance abuse, abnormal hepatic
or renal function, gastro-esophageal reflux disease, a
medical history of ulcers, or women planning a preg-
nancy or breastfeeding. Exclusions were made for indivi-
duals on medications for chronic health conditions.
Sixty-five adults were screened of which 11 were ineli-
gible and 9 withdrew from the study prior to
randomization. Three individuals did not continue the
study after the baseline visit and were not included in
the current analysis. The final study population included
14 men and 28 women. The study was approved by the
institutional review boards of the Beth Israel Deaconess
Medical Center and the Harvard School of Public Health
and all participants provided written informed consent.
The clinical trial registration number is NCT00305097.
After two weeks of caffeine abstention, participants
attended the baseline visit in the morning after fasting
overnight for at least 12 hours. Participants were rando-
mized to either caffeinated coffee, decaffeinated coffee,
or no coffee (control) treatment groups. Treatment
assignments for the coffee arms were blinded to the
study participants, investigators, and laboratory staff.
Participants in the coffee treatment groups were given
five two-gram portions of instant coffee per day (caffein-
ated or decaffeinated Nestlé’s Taster’s ChoiceW) to be
mixed with approximately 6 ounces of boiling water and
consumed with every meal and mid-morning and mid-
afternoon. Non-caloric sweetener and non-dairy creamerwere also provided. Participants in the control group
were instructed to drink the equivalent amount of water
at the same intervals throughout the day.
At baseline, week 4, and week 8, the study visits
included a physical examination, anthropometric mea-
surements, and a fasting blood draw. Sex hormone-
binding globulin and all other endogenous sex hormones
were measured via Access chemiluminescent immuno-
assay (Beckman Coulter, Fullerton, CA). Free testoster-
one and free estradiol were calculated using the
Sodergard formula which is based on the law of mass ac-
tion and assumptions of equilibrium binding [10].
All analyses were performed separately for men and
women. Using general linear models, we evaluated the
change from baseline in SHBG, testosterone (total and
free), estradiol (total and free), testosterone to estradiol
ratio, and DHEAs regressed on treatment group as a
main effect with baseline log values of the dependent
variable and age as additional covariates. Both covariates
were grand mean centered to improve the interpretabil-
ity of the estimates. Because SHBG and sex hormones
did not follow a normal distribution, the variables were
log-transformed and subsequently back-transformed to
yield geometric means. Differences between caffeinated
and decaffeinated coffee compared with the control
group were based on linear contrasts. The adjusted geo-
metric means with standard errors were reported by
treatment, and 95% confidence intervals (CI) were com-
puted. In addition, we calculated the difference between
the treatment groups versus control for change from
baseline. This yielded a ratio (or percentage when sub-
tracting the value one and multiplying by 100), given the
principles of logged numbers.
Statistical significance was evaluated at an alpha level
of 0.05. The Statistical Analysis System version 9.1.3 was
used for all analyses (SAS Institute, Cary, NC).
Results
In men, mean concentrations were 25.3 nmol/L for
SHBG, 411.3 ng/dL for testosterone, 8.0 ng/dL for
free testosterone, 24.9 pg/mL for estradiol, 0.5 pg/mL
for free estradiol, and 194.9 ng/mL for DHEAs. In
women, mean concentrations were 51.5 nmol/L for
SHBG, 35.9 ng/dL for testosterone, 0.5 ng/dL for free
testosterone, 63.2 pg/mL for estradiol, 1.0 pg/mL for free
estradiol, and 133.7 ng/mL for DHEAs. The baseline
characteristics of the study population are shown in
Table 1 according to treatment group. Ten women were
postmenopausal. The average age was 40 years for both
men (range 23–72 years) and women (18–69 years).
Mean body mass index was 30.3 kg/m2 for men and
29.0 kg/m2 for women. All participants included in the
analysis population completed the 8-week trial with the
exception of one female participant who discontinued
Table 1 Baseline characteristics for men and women by treatment group
MEN WOMEN
Caffeinated Decaffeinated No Coffee Caffeinated Decaffeinated No Coffee
(N = 4) (N = 4) (N = 6 ) (N = 10) (N = 9) (N = 9 )
Age (years) 37.2 (3.5) 35.0 (6.4) 47.3 (18.4) 40.0 (8.8) 43.2 (16.6) 38.4 (18.0)
Body mass index (kg/m2) 30.8 (1.9) 29.5 (2.7) 30.4 (1.3) 28.4 (1.9) 29.5 (2.2) 29.2 (2.5)
Waist circumference (cm) 97.7 (7.3) 102.9 (8.3) 102.0 (6.8) 85.9 (10.6) 90.9 (7.8) 88.3 (7.4)
Postmenopausal (n (%)) n/a n/a n/a 2 (20) 5 (56) 3 (33)
SHBG (nmol/L) 21.4 (13.7, 33.5) 19.5 (11.7, 32.5) 29.3 (18.2, 47.3) 52.6 (35.2, 78.6) 42.9 (28.6, 64.2) 38.1 (25.4, 57.0)
Testosterone (ng/dL) 387.9 (303.6, 495.7) 342.3 (259.0, 452.2) 475.5 (356.2, 634.6) 28.2 (19.2, 41.5) 27.3 (18.1, 41.1) 34.9 (23.2, 52.4)
Free testosterone (ng/dL) 8.0 (6.2, 10.3) 7.1 (5.3, 9.5) 8.0 (5.9, 10.7) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5) 0.4 (0.2, 0.8)
Estradiol (pg/mL) 24.0 (17.0, 33.8) 21.7 (14.7, 32.1) 26.2 (17.5, 39.3) 47.4 (26.2, 85.8) 34.8 (18.6, 65.2) 47.7 (25.5, 89.4)
Free estradiol (pg/mL) 0.5 (0.3, 0.7) 0.4 (0.3, 0.7) 0.5 (0.3, 0.7) 0.8 (0.4, 1.4) 0.5 (0.3, 1.0) 0.8 (0.4, 1.5)
Testosterone : Estradiol 16.2 (11.4, 23.0) 15.8 (10.6, 23.5) 18.1 (12.0, 27.4) 0.6 (0.3, 1.2) 0.8 (0.4, 1.6) 0.7 (0.4, 1.5)
DHEAs (ng/mL) 184.1 (113.7, 298.1) 160.0 (92.4, 277.2) 161.7 (96.8, 270.1) 115.2 (82.7, 160.5) 98.1 (69.0, 139.3) 117.4 (82.7, 166.7)
n/a, not applicable; SHBG, sex hormone-binding globulin; DHEAs, dehydroepiandrosterone sulfate.
Data are arithmetic means (standard deviation) for continuous variables and percentages for categorical variables. Age-adjusted geometric means (95%
confidence in intervals) are presented for hormone concentrations which did not follow a normal distribution.
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were reported during the course of the intervention.
Adjusted geometric means followed by percent change
from baseline estimates for the endpoints are shown for
men (Table 2) and women (Table 3). At the final study
visit (week 8) there were no significant differences for any
of the outcomes. In addition, we did not observe an effect
of coffee intake on SHBG levels in men, although a bor-
derline significant increase for decaffeinated coffee was
observed among women [difference in change from base-
line (CFB): 38%; 95% CI: 1%, 88%; p = 0.04] compared
with consuming no coffee at week 4. In contrast, several
significant differences between the treatment groups were
found at week 4. Among men, consumption of caffeinated
coffee increased total testosterone (CFB: 67%; 95% CI: 4%,
168%; p = 0.04) and decreased total and free estradiol
(CFB total: -47%; 95% CI: -19%, -65%; p = 0.01 and CFB
free: -43%; 95% CI: -10%, -64%; p = 0.02). Among women,
decaffeinated coffee decreased total and free testosterone
(CFB total: -60%; 95% CI: -24%, -79%; p = 0.01 and CFB
free: -68%: 95% CI: -26%, -86%; p = 0.01) and caffeinated
coffee decreased total testosterone (p = 0.04). The ratio of
testosterone to estradiol, a potential marker for aromatase
activity, was significantly increased in men in the caffein-
ated coffee group at week 4 (CFB: 189%; 95% CI: 39%,
502%; p = 0.01) whereas no significant differences were
observed for women. We did not observe any significant
effects for DHEAs in either men or women.
Discussion
In this randomized controlled trial with a caffeinated
and decaffeinated coffee intervention, we did not find
evidence of a consistent effect on SHBG levels inoverweight men or women. All significant effects for
SHBG and the hormone measurements were limited to
the week 4 visit with no significant effects observed at
the time of the final week 8 visit.
Previous studies on coffee or caffeine consumption in
relation to SHBG and sex hormone concentrations all
had a cross-sectional design and have been almost exclu-
sively conducted in women. The Additional file 1: Table
S1 shows the characteristics and findings from these
studies. Our results for caffeinated coffee and SHBG are
consistent with two previous cross-sectional studies
[11,12] which did not find an association with consump-
tion of caffeine or caffeinated coffee, whereas other stud-
ies did detect direct associations [2,3,6-8]. In contrast to
our findings for caffeinated coffee, we found slightly ele-
vated SHBG levels in the decaffeinated group as com-
pared with the control group at week 4 in women, but
this observation was limited to women and not observed
at week 8 and may well represent a chance finding. Few
studies have specifically studied decaffeinated coffee, but
the Women’s Health Study [3] observed no association
between decaffeinated coffee and SHBG.
Our results in women of a decrease in total testoster-
one levels at week 4 in both caffeinated and decaffei-
nated arms are not consistent with the lack of
association between coffee consumption and testoster-
one in previous observational studies [2,3,7]. We did not
observe a significant effect of coffee consumption on es-
tradiol concentrations among the women in our trial.
This finding agrees with four cross-sectional studies that
also found no association between caffeinated coffee
consumption and estradiol [3,6,7,11]. In contrast, an in-
verse association between coffee consumption and luteal
Table 2 Sex hormone-binding globulin and endogenous sex hormones by treatment group at week 4 and week 8 in
men
Week 4 Week 8
Value (95% confidence interval) Value (95% confidence interval)
Caffeinated Decaffeinated No Coffee Caffeinated Decaffeinated No Coffee
Coffee Coffee Coffee Coffee
(N = 4) (N = 4) (N = 6) (N = 4) (N = 4) (N = 6)
SHBG (nmol/L)
Geometric means† 20.7 (15.2, 28.1) 23.9 (16.7, 34.2) 23.0 (16.3, 32.4) 23.1 (19.4, 27.5) 25.0 (20.4, 30.6) 23.1 (19.0, 28.0)
Difference in CFB (%)‡ −10.2 (−44.7, 45.7) 3.8 (−39.3, 77.4) Reference 0.2 (−23.8, 31.8) 8.2 (−20.1, 46.5) Reference
Testosterone (ng/dL)
Geometric means† 546.2 (412.8, 722.7) 493.6 (350.5, 695.1) 327.4 (227.7, 470.8) 403.8 (349.8, 466.0) 386.1 (324.0, 460.1) 373.1 (309.8, 449.5)
Difference in CFB (%)‡ 66.8 (3.9, 167.9) a 50.8 (−13.1, 161.6) Reference 8.2 (−15.1, 37.9) 3.5 (−22.0, 37.2) Reference
Free testosterone (ng/dL)
Geometric means† 11.7 (7.0, 19.6) 9.2 (5.1, 16.8) 6.6 (3.6, 12.2) 8.0 (6.6, 9.6) 7.6 (6.1, 9.5) 7.0 (5.6, 8.7)
Difference in CFB (%)‡ 76.0 (−21.8, 295.9) 39.0 (−42.8, 238.0) Reference 14.5 (−14.9, 54.1) 9.7 (−20.8, 51.9) Reference
Estradiol (pg/mL)
Geometric means† 22.5 (17.2, 29.5) 35.9 (26.3, 49.0) 42.6 (30.9, 58.7) 25.2 (19.3, 32.8) 27.1 (20.0, 36.9) 20.7 (15.1, 28.4)
Difference in CFB (%)‡ −47.1 (−65.5, -19.1) b −15.8 (−47.3, 34.5) Reference 21.7 (−20.0, 85.3) 31.2 (−17.4, 108.2) Reference
Free estradiol (pg/mL)
Geometric means† 0.4 (0.3, 0.6) 0.7 (0.5, 0.9) 0.8 (0.6, 1.1) 0.5 (0.4, 0.6) 0.5 (0.4, 0.71) 0.4 (0.3, 0.6)
Difference in CFB (%)‡ −42.8 (−63.7, -9.9) a −12.7 (−46.5, 42.4) Reference 21.4 (−21.9, 88.8) 31.1 (−18.5, 110.9) Reference
Testosterone : Estradiol
Geometric means† 24.2 (15.2, 38.4) 12.6 (7.5, 21.4) 8.4 (4.8, 14.5) 16.1 (12.2, 21.3) 14.6 (10.6, 20.1) 17.5 (12.5, 24.4)
Difference in CFB (%)‡ 188.8 (38.5, 502.1) b 50.9 (−31.7, 233.6) Reference −8.0 (−41.1, 43.8) −16.6 (−48.5, 35.1) Reference
DHEAs (ng/mL)
Geometric means† 178.0 (161.1, 196.8) 165.4 (147.7, 185.3) 159.8 (143.7, 177.6) 193.9 (168.1, 223.7) 164.1 (139.6, 193.0) 162.9 (140.1, 189.5)
Difference in CFB (%)‡ 11.4 (−4.2, 29.5) 3.5 (−12.0, 21.7) Reference 19.0 (−4.0, 47.6) 0.7 (−20.1, 27.0) Reference
SHBG, sex hormone-binding globulin; CFB, change from baseline; DHEAs, dehydroepiandrosterone sulfate.
† Geometric mean as the dependent variable with treatment as a main effect, and baseline log value (grand mean centered) and age (grand mean centered) as
covariates.
‡ Difference in change from baseline compared to No Coffee (i.e., ratio of ratios) adjusted for the above covariates.
a p < 0.05 compared to No Coffee.
b p < 0.01 compared to No Coffee.
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premenopausal women [2] and a direct association was
observed for follicular estradiol in another study among
premenopausal women [12]. It is currently unclear
whether the discrepancy between our findings and previ-
ous studies is due to the limited power or duration of
our trial or methodological limitations of the cross-
sectional studies.
As mentioned previously, little data has been pub-
lished on coffee consumption and SHBG or sex hor-
mones in men. Our finding that caffeinated coffee, but
not decaffeinated coffee, significantly increased total tes-
tosterone and decreased both total and free estradiol
after 4 weeks suggests that caffeine may act as an aroma-
tase (or CYP19) inhibitor. One intervention trial [13]
found that consumption of two cups of instant coffeehad no acute effect on testosterone or estradiol concen-
trations after 30 minutes.
This is the first randomized controlled trial investigat-
ing the effects of caffeinated and decaffeinated coffee on
SHBG and sex hormones. Attrition was low among par-
ticipants and non-fasting blood samples measured for
caffeine and its major metabolites at the 6-week visit
indicated that compliance was high. Our study also had
several limitations that need to be considered. Most not-
ably, our study has a small sample size which may have
limited our ability to detect modest effects on SHBG
and sex hormone levels. Thus, findings should be inter-
preted with caution and require confirmation in larger
trials. In addition, given the small sample size, stratifying
analyses by menopausal status was not appropriate. In-
clusion of age in the analysis of covariance models was
Table 3 Sex hormone-binding globulin and endogenous sex hormones by treatment group at week 4 and week 8 in
women
Week 4 Week 8
Value (95% confidence interval) Value (95% confidence interval)
Caffeinated Decaffeinated No Coffee Caffeinated Decaffeinated No Coffee
Coffee Coffee Coffee Coffee
(N = 10) (N = 9) (N = 9) (N = 10) (N = 9) (N = 9)
SHBG (nmol/L)
Geometric means† 43.8 (35.2, 54.5) 52.8 (42.5, 65.5) 38.2 (30.7, 47.6) 44.2 (37.3, 52.4) 45.8 (38.7, 54.1) 44.2 (37.3, 52.4)
Difference in CFB (%)‡ 14.6 (−16.2, 56.7) 38.0 (1.5, 87.7) a Reference −0.0 (−21.6, 27.4) 3.6 (−18.4, 31.5) Reference
Testosterone (ng/dL)
Geometric means† 51.3 (33.5, 78.6) 39.0 (24.8, 61.4) 98.3 (62.3, 155.2) 35.1 (26.2, 47.0) 32.4 (23.8, 44.2) 37.3 (27.3, 51.0)
Difference in CFB (%)‡ −47.8 (−72.1, -2.3) a −60.3 (−79.3, -24.0) b Reference −5.9 (−38.7, 44.3) −13.1 (−44.3, 35.5) Reference
Free testosterone (ng/dL)
Geometric means† 0.6 (0.3, 1.0) 0.4 (0.2, 0.7) 1.2 (0.7, 2.1) 0.4 (0.3, 0.6) 0.3 (0.2, 0.5) 0.4 (0.3, 0.6)
Difference in CFB (%)‡ −51.1 (−78.7, 12.0) −67.8 (−86.0, -26.2) b Reference −6.0 (−47.5, 68.5) −13.3 (−51.6, 55.4) Reference
Estradiol (pg/mL)
Geometric means† 37.9 (26.5, 54.2) 42.6 (29.0, 62.3) 42.9 (28.7, 64.1) 41.8 (24.8, 70.6) 39.7 (22.7, 69.4) 40.6 (23.3, 70.6)
Difference in CFB (%)‡ −11.8 (−48.4, 50.8) −0.9 (−43.2, 73.2) Reference 3.2 (−51.7, 120.5) −2.1 (−55.8, 116.6) Reference
Free estradiol (pg/mL)
Geometric means† 0.6 (0.4, 0.9) 0.6 (0.4, 0.9) 0.7 (0.5, 1.1) 0.7 (0.4, 1.1) 0.6 (0.3, 1.0) 0.6 (0.4, 1.1)
Difference in CFB (%)‡ −19.3 (−56.1, 48.3) −13.4 (−53.5, 61.3) Reference 2.9 (−52.2, 121.6) −5.2 (−56.8, 108.2) Reference
Testosterone : Estradiol
Geometric means† 1.4 (0.8, 2.3) 1.0 (0.6, 1.7) 2.1 (1.2, 3.8) 0.8 (0.5, 1.5) 0.8 (0.4, 1.5) 0.9 (0.5, 1.7)
Difference in CFB (%)‡ −36.0 (−71.0, 41.4) −54.1 (−79.6, 3.3) Reference −9.9 (−61.7, 111.9) −9.6 (−62.6, 118.3) Reference
DHEAs (ng/mL)
Geometric means† 113.8 (101.0, 128.1) 101.7 (89.6, 115.5) 100.0 (87.5, 114.4) 111.7 (101.0, 123.6) 102.9 (92.3, 114.6) 120.4 (108.2, 134.1)
Difference in CFB (%)‡ 13.7 (−4.9, 36.0) 1.7 (−15.6, 22.5) Reference −7.2 (−19.9, 7.4) −14.6 (−26.7, -0.4) Reference
SHBG, sex hormone-binding globulin; CFB, change from baseline; DHEAs, dehydroepiandrosterone sulfate.
† Geometric mean as the dependent variable with treatment as a main effect, and baseline log value (grand mean centered) and age (grand mean centered) as
covariates.
‡ Difference in change from baseline compared to No Coffee (i.e., ratio of ratios) adjusted for the above covariates.
a p < 0.05 compared to No Coffee.
b p < 0.01 compared to No Coffee.
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date, it is clear that heterogeneity among the observa-
tional studies in timing of the hormone measurements
in women has most likely led to some of the divergent
findings. We inquired about the last menstrual period or
menopausal status, in addition to having the two follow-
up visits timed approximately four weeks apart to reduce
the variation in measurement for sex hormones by fol-
licular and luteal cycle timing. However, it is plausible
that inadequate control for menopausal status attenu-
ated our results given the variability in the women’s ages
and that, for example, the majority of postmenopausal
women were in the decaffeinated coffee group. In our
trial, lack of finding any significant effects at the 8-week
visit for any of the measurements lends to the hypothesisthat habituation may have occurred by the time of the
final 8-week visit. Longer randomized trials with larger
sample size will be necessary to elucidate the temporality
of the potential effects.
In this randomized controlled trial with caffeinated
and decaffeinated coffee interventions, we did not find
evidence of a consistent effect on SHBG levels in over-
weight men or women. This contrasts with the beneficial
effects of coffee consumption on adiponectin and fetuin-
A levels previously reported in this trial [9], suggesting
that the SHBG level is not the major intermediate of the
putative effect of coffee consumption on a lower risk of
T2DM. Our findings necessitate further examination in
a larger intervention trial of the effects of coffee on sex
hormones to elucidate if this is a potential intermediary
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coffee intake and T2DM.
Additional file
Additional file 1: Table S1. Summary of the observational evidence for
the relation between coffee and caffeine intake, SHBG and sex hormone
levels.
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